临床研究团队

•       干预性/非干预性临床研究设计与实施

•       临床数据库构建与数据挖掘

•       基于真实世界的临床药物治疗评价

•       临床预测模型构建

药学服务团队

•       精准药学门诊

•       临床药学查房与医嘱干预

•       患者管理与药物服务

循证药学团队

•       药物治疗的国际化快速临床指南

•       临床药物治疗路径

•       药物疗效性、安全性和经济性评价

多组学研究团队

•       构建疾病预警模型

•       疾病关键基因及生物标志物发现

•       基于组学数据的个体化用药模型

药理研究团队

•       动物/细胞模型

•       标志物验证

•       机制探索

1. 神经递质联合γ-氨基丁酸代谢相关GABA-T基因用于奥氮平-北京市科协(202101-202312)

2. 奥马珠单抗治疗哮喘患者的临床药效预测模型建立及药学实践 -北京市呼吸病研究所(202206-202306)

3. 基于快速临床指南和实施科学的单病种质量控制的 合理用药管理体系构建与应用-国家卫生健康委医院管理研究所(202209-202409)

4. 抗抑郁药物临床疗效的药物代谢基因相关性分析及预测模型建立-首都医科大学附属北京朝阳医院(202209-202402)

5. 塞利尼索片（希威奥）上市后安全性终点检测真实世界研究-临床使用安全性及不良反应信息收集-北京精准医学会(202205-202306)

6. ABAT-GABA在抗精神病药物奥氮平精准用药的应用研究-中国药学会(202201-202312)

7. 食管癌早诊标志物及早期筛查试剂盒的验证研究-中央民族大学(202201-202412)

8. ABAT基因多态性通过调控线粒体功能影响奥氮平治疗精神分裂症药效的机制研究-首都医科大学(202301-202312)

9. 高层次公共卫生技术人才建设项目学科骨干培养对象-北京市卫健委(202301-202512)

1.        Yang H, Wang Z, Jiang C, ZhangY, Zhang Y, Xu M, Zhang Y, Wang Y, Liu X, An Z*, Tong Z*. Oral azvudine formild-to-moderate COVID-19 in high risk, nonhospitalized adults: Results of areal-world study. J Med Virol. 2023 Jul;95(7):e28947. doi: 10.1002/jmv.28947.PMID: 37470209.

2.        Yang H*, Wang Z*, Zhang Y, XuM, Wang Y, Zhang Y, Liu X, An Z*, Tong Z*. Clinical characteristics and factorsfor serious outcomes among outpatients infected with the Omicron subvariantBF.7. J Med Virol. 2023 Aug;95(8):e28977. doi: 10.1002/jmv.28977. PMID:37635385.

3.        Wang X, Turhon M, Yang X, LiuJ, Zhang H, Li T, Song D, Zhao Y, Guan S, Maimaitili A, Wang Y, Feng W, Wan J,Mao G, Shi H, An Z*, Wang Y*. Could statin improve outcomes after pipelineembolization for intracranial aneurysms in a real-world setting? Ther AdvNeurol Disord. 2023 May 10;16:17562864231170517. doi:10.1177/17562864231170517. PMID: 37187463; PMCID: PMC10176586.

4.        Zhang Y, Ran L, Liang Y, ZhangY, An Z*. Safety analysis of pemigatinib leveraging the US Food and Drugadministration adverse event reporting system. Front Pharmacol. 2023 Jul24;14:1194545. doi: 10.3389/fphar.2023.1194545. PMID: 37554985; PMCID:PMC10405447.

5.        Wang X#, Wang C#, Zhang Y*, AnZ*. Effect of pharmacogenomics testing guiding on clinical outcomes in majordepressive disorder: a systematic review and meta-analysis of RCT. BMCPsychiatry. 2023 May 12;23(1):334. doi: 10.1186/s12888-023-04756-2. PMID:37173736; PMCID: PMC10176803.

6.        Hu T#*, Ren L#, Li H, An Z*.Effects of Vitamin D supplementation or deficiency on metabolic phenotypes inmice of different sexes. J Steroid Biochem Mol Biol. 2023 May;229:106250. doi:10.1016/j.jsbmb.2023.106250. Epub 2023 Jan 25. PMID: 36708934.

7.        Zhang J, Han L, Liu H, ZhangH*, An Z*. Metabolomic analysis reveals the metabolic disturbance in aorticdissection: Subtype difference and accurate diagnosis. Nutr Metab CardiovascDis. 2023 Aug;33(8):1556-1564.

8.        Wang X, Luo L, Wang Y, An Z*.Effect of Platelet Function Testing Guidance on Clinical Outcomes for Patientswith Intracranial Aneurysms Undergoing Endovascular Treatment. AJNR Am JNeuroradiol. 2023 Aug;44(8):928-933. doi: 10.3174/ajnr.A7923. Epub 2023 Jul 6.PMID: 37414457; PMCID: PMC10411848.

9.        Yang H, Zhang Y, Feng X*, AnZ*. Bleeding Complications in Vancomycin-Induced Thrombocytopenia: A Real-worldPostmarketing Pharmacovigilance Analysis. Clin Ther. 2023 Sep;45(9):868-872.doi: 10.1016/j.clinthera.2023.06.022. Epub 2023 Aug 26. PMID: 37640615.

10.    Ma Z, Pei J, Zhang Y, Li H, SunD, Zhang Y*, An Z*. Interstitial pneumonitis associated with EGFR/ ALK tyrosinekinase inhibitors used in non-small cell lung cancer: an observational,retrospective, pharmacovigilance study. Expert Opin Drug Saf. 2023Mar;22(3):237-242. doi: 10.1080/14740338.2022.2110235. Epub 2022 Aug 5. PMID:35924402.

11.    Liu H, Yu X, Hu T, Han F, AnZ*, Zhao R*. Simultaneous determination of four antibiotics in human plasma byhigh-performance LC-MS/MS: application to therapeutic drug monitoring.Bioanalysis. 2023 Mar;15(5):269-282.

12.    Ye Z, Zhou T, Zhang M, Zhou J,Xie F, Hill MD, Smith EE, Busse JW, Zhang Y, Liu Y, Wang X, Ma Z, An Z*.Cost-effectiveness of endovascular thrombectomy with alteplase versusendovascular thrombectomy alone for acute ischemic stroke secondary to largevessel occlusion. CMAJ Open. 2023 May 16;11(3):E443-E450. doi:10.9778/cmajo.20220096. PMID: 37192770; PMCID: PMC10205869.

13.    Ye Z, Busse JW, Hill MD,Lindsay MP, Guyatt GH, Prasad K, Agarwal A, Beattie C, Beattie J, Dodd C, HeranMKS, Narayan S, Chartúir NN, O'Donnell M, Resmini I, Sacco S, Sylaja PN,Volders D, Wang X, Xie F, Zachrison KS, Zhang L, Zhong H, An Z*, Smith EE.Endovascular thrombectomy and intravenous alteplase in patients with acuteischemic stroke due to large vessel occlusion: A clinical practice guideline. J Evid Based Med. 2022 Sep;15(3):263-271. doi: 10.1111/jebm.12493. Epub 2022 Sep19. PMID: 36123777.

14.    Ma Z#, Sun X#, Zhang Y, Li H,Sun D, An Z*, Zhang Y*. Risk of Thromboembolic Events in Cancer PatientsTreated with Immune Checkpoint Inhibitors: A Meta-analysis of RandomizedControlled Trials. Thromb Haemost. 2022 Jun 30. doi: 10.1055/s-0042-1749185.Epub ahead of print. PMID: 35772727.

15.    Wang X, Ye Z, Busse JW, HillMD, Smith EE*, Guyatt GH, Prasad K, Lindsay MP, Yang H, Zhang Y, Liu Y, Tang B,Wang X, Wang Y, Couban RJ, An Z*. Endovascular thrombectomy with or withoutintravenous alteplase for acute ischemic stroke due to large vessel occlusion:a systematic review and meta-analysis of randomized trials. Stroke Vasc Neurol.2022 Jun 20:svn-2022-001547. doi: 10.1136/svn-2022-001547. Epub ahead of print.PMID: 35725244.

16.    Du P*, Wang G, Hu T, Li H, AnZ*. Integration Analysis of Pharmacokinetics and Metabolomics to PredictMetabolic Phenotype and Drug Exposure of Remdesivir. Front Pharmacol. 2022 Jan5;12:779135. doi: 10.3389/fphar.2021.779135. PMID: 35069201; PMCID: PMC8766850.

17.    An Z#, Zhao R#, Han F, Sun Y,Liu Y*, Liu L*. Potential Serum Biomarkers Associated with Premature Rupture ofFetal Membranes in the First Trimester. Front Pharmacol. 2022 Jul 8;13:915935.doi: 10.3389/fphar.2022.915935. PMID: 35873552; PMCID: PMC9304655.

18.    Hu T*, Sun Y, An Z*. Dose- andtime-dependent manners of moxifloxacin induced liver injury by targetedmetabolomics study. Front Pharmacol. 2022 Sep 16;13:994821. doi:10.3389/fphar.2022.994821. PMID: 36188611; PMCID: PMC9525095.

19.    Yang H, Yu X, An Z*. CutaneousToxicity Associated With Enfortumab Vedotin: A Real-Word Study Leveraging U.S.Food and Drug Administration Adverse Event Reporting System. Front Oncol. 2022Jan 19;11:801199. doi: 10.3389/fonc.2021.801199. PMID: 35127510; PMCID:PMC8807512.

20.    Hu Y#, Lu W#, Tang B, Zhao Z*,An Z*. Urinary incontinence as a possible signal of neuromuscular toxicityduring immune checkpoint inhibitor treatment: Case report and retrospectivepharmacovigilance study. Front Oncol. 2022 Sep 12;12:954468. doi:10.3389/fonc.2022.954468. PMID: 36172143; PMCID: PMC9510979.

21.    Cong L#, Wan Z#, Li P#, Liu D,He J*, An Z*, Liu L. Metabolic, genetic, and pharmacokinetic parameters for theprediction of olanzapine efficacy. Eur J Pharm Sci. 2022 Aug 15:106277. doi:10.1016/j.ejps.2022.106277. Epub ahead of print. PMID: 35981664.

22.    Ma Z, Zhang Y, Zhu M, Feng L,Zhang Y*, An Z*. Interstitial lung disease associated with anti-HER2 anti-bodydrug conjugates: results from clinical trials and the WHO's pharmacovigilance database.Expert Rev Clin Pharmacol. 2022 Nov;15(11):1351-1361. doi:10.1080/17512433.2022.2121705. Epub 2022 Sep 16. PMID: 36111954.

23.    Du P*, Xuan L, An Z*, Zhang Y*.Development and validation of a robust and sensitive HPLC-MS/MS method for thequantitation of MRTX849 in plasma and its application in pharmacokinetics.Analyst. 2022 Mar 14;147(6):1175-1180. doi: 10.1039/d1an01928g. PMID: 35195627.

24.    Zhang Y#, Ma Z#, Sun X, FengX*, An Z*. Interstitial lung disease in patients treated with Cyclin-DependentKinase 4/6 inhibitors: A systematic review and meta-analysis of randomizedcontrolled trials. Breast. 2022 Apr;62:162-169. doi:10.1016/j.breast.2022.02.011. Epub 2022 Feb 22. PMID: 35219113; PMCID:PMC8873944.

25.    Hu T*, Zhang W, Han F, Zhao R,Liu L, An Z*. Plasma fingerprint of free fatty acids and their correlationswith the traditional cardiac biomarkers in patients with type 2 diabetescomplicated by coronary heart disease. Front Cardiovasc Med. 2022 Jul22;9:903412. doi: 10.3389/fcvm.2022.903412. PMID: 35935651; PMCID: PMC9355375.

26.    Tang B#, Zhang Y#, Wang Y, WangX, An Z*, Yu X*. Effect of bariatric surgery on long-term cardiovascularoutcomes: a systematic review and meta-analysis of population-based cohortstudies. Surg Obes Relat Dis. 2022 May 16:S1550-7289(22)00202-7. doi:10.1016/j.soard.2022.05.007. Epub ahead of print. PMID: 35717432.

27.    An Z*, Sun Y, Shi C, Liu L*.Metabonomic and transcriptomic analyses of Tripterygium glycosidestablet-induced hepatotoxicity in rats. Drug Chem Toxicol. 2022 May 23:1-15. doi:10.1080/01480545.2022.2077360. Epub ahead of print. PMID: 35603506.

28.    Sun Y, Cong L, Yang S, Zhao R,An Z*, Liu L*. Moxifloxacin Induced Liver Injury by Causing LachnospiraceaeDeficiency and Interfering with Butyric Acid Production through Gut-Liver Axis.Dis Markers. 2022 Apr 29;2022:9302733. doi: 10.1155/2022/9302733. PMID:35531479; PMCID: PMC9076306.

29.    Hu T#, An Z#, Li H, Liu Y, XiaL, Qiu L, Yao A, Ma L*, Liu L*. UHPLC-MS/MS-Based Metabolomics and ClinicalPhenotypes Analysis Reveal Broad-Scale Perturbations in Early Pregnancy Relatedto Gestational Diabetes Mellitus. Dis Markers. 2022 Aug 24;2022:4231031. doi:10.1155/2022/4231031. PMID: 36061360; PMCID: PMC9433254.

30.    Zhao R#, An Z#, Sun Y, Xia L,Qiu L, Yao A, Liu Y*, Liu L*. Metabolic profiling in early pregnancy andassociated factors of folate supplementation: A cross-sectional study. ClinNutr. 2021 Sep;40(9):5053-5061. doi: 10.1016/j.clnu.2021.01.012. Epub 2021 Jan23. PMID: 34455263.

31.    Hu T#*, Li H#, Xu B, Du P, LiuL, An Z*. Parallel derivatization strategy for comprehensive profiling ofunconjugated and glycine-conjugated bile acids using Ultra-high performanceliquid chromatography-tandem mass spectrometry. J Steroid Biochem Mol Biol.2021 Nov;214:105986. doi: 10.1016/j.jsbmb.2021.105986. Epub 2021 Aug 25. PMID:34454009.

32.    Hu T, Sun Y, Li H, Du P, LiuL*, An Z*. Dual derivatization strategy for the comprehensive quantificationand double bond location characterization of fatty acids by ultra-highperformance liquid chromatography-tandem mass spectrometry. J Chromatogr A.2021 Feb 22;1639:461939. doi: 10.1016/j.chroma.2021.461939. Epub 2021 Jan 23.PMID: 33530009.

33.    Zhou H#, Sun X#, Lyu S, Yu X,Li R, Wang H*, An Z*. Evaluation of Tigecycline Utilization and Trends inAntibacterial Resistance from 2018 to 2021 in a Comprehensive Teaching Hospitalin China. Infect Drug Resist. 2023 Feb 14;16:879-889. doi: 10.2147/IDR.S395158.PMID: 36820081; PMCID: PMC9938701.

34.    An Z#, Wang X#, Li P#, He J,Liu L*. Exploring the metabolic characteristics and pharmacokinetic variationof paroxetine in healthy volunteers using a pharmacometabonomic approach. JPharm Biomed Anal. 2021 Sep 10;204:114224. doi: 10.1016/j.jpba.2021.114224.Epub 2021 Jun 24. PMID: 34265484.

35.    Li B, Yang S, Ye J, Chu S, ChenN*, An Z*. Flavin-containing monooxygenase 1 deficiency promotesneuroinflammation in dopaminergic neurons in mice. Neurosci Lett. 2021 Nov1;764:136222. doi: 10.1016/j.neulet.2021.136222. Epub 2021 Sep 6. PMID: 34500002.

36.    An Z*, Shi C, Li P, Liu L*.Stability of amino acids and related amines in human serum under differentpreprocessing and pre-storage conditions based on iTRAQ®-LC-MS/MS. Biol Open.2021 Feb 26;10(2):bio055020. doi: 10.1242/bio.055020. PMID: 33563610; PMCID:PMC7928226.

37.    Liu H#, Zhao Z#, Wang Y, Liu L,Yang Y, An Z*. Study on the Relationship between Rivaroxaban and Factor XaActivity in Blood Based on HPLC-MS/MS. Curr Drug Metab. 2021;22(14):1132-1138.doi: 10.2174/1389200222666211126093627. PMID: 34825867.

38.    Wang X, Tang B, Liu Y, Wang X,Wang S, An Z*, Wang H*. Clinical practice guidelines for management of dualantiplatelet therapy in patients with noncardiac surgery: A critical appraisalusing the AGREE II instrument. J Clin Pharm Ther. 2022 May;47(5):652-661. doi:10.1111/jcpt.13593. Epub 2021 Dec 23. PMID: 34939677.

39.    Hu T#, An Z#, Sun Y, Wang X, DuP, Li P, Chi Y*, Liu L*. Longitudinal Pharmacometabonomics for PredictingMalignant Tumor Patient Responses to Anlotinib Therapy: Phenotype, Efficacy,and Toxicity. Front Oncol. 2020 Nov 12;10:548300. doi:10.3389/fonc.2020.548300. PMID: 33282726; PMCID: PMC7689013.

40.    Liu D#, An Z#, Li P, Chen Y,Zhang R, Liu L*, He J*, Abliz Z. A targeted neurotransmitter quantification andnontargeted metabolic profiling method for pharmacometabolomics analysis ofolanzapine by using UPLC-HRMS. RSC Adv. 2020 May 13;10(31):18305-18314. doi:10.1039/d0ra02406f. PMID: 35517196; PMCID: PMC9053711.

41.    Hu T, Shi C, Liu L, Li P, SunY, An Z*. A single-injection targeted metabolomics profiling method fordetermination of biomarkers to reflect tripterygium glycosides efficacy andtoxicity. Toxicol Appl Pharmacol. 2020 Jan 15;389:114880. doi:10.1016/j.taap.2020.114880. Epub 2020 Jan 14. PMID: 31945383.

42.    Hu T#*, Li H#, Liu H, Cong L,Liu L, An Z*. High throughput UHPLC-MS/MS method for the simultaneousquantification of six vitamin D metabolites: application for vitamin Ddetermination in patients after liver or kidney transplantation. Anal Methods.2020 Dec 7;12(46):5591-5600. doi: 10.1039/d0ay01088j. PMID: 33174880.

43.    Hu T#, An Z#, Shi C, Li P, LiuL*. A sensitive and efficient method for simultaneous profiling of bile acidsand fatty acids by UPLC-MS/MS. J Pharm Biomed Anal. 2020 Jan 30;178:112815.doi: 10.1016/j.jpba.2019.112815. Epub 2019 Aug 15. PMID: 31639597.

44.    An Z, Hu T, Lv Y, Li P, Liu L*.Targeted amino acid and related amines analysis based on iTRAQ®-LC-MS/MS fordiscovering potential hepatotoxicity biomarkers. J Pharm Biomed Anal. 2020 Jan30;178:112812. doi: 10.1016/j.jpba.2019.112812. Epub 2019 Aug 19. PMID:31639596.

45.    An Z, Li C, Lv Y, Li P, Wu C,Liu L*. Metabolomics of Hydrazine-Induced Hepatotoxicity in Rats forDiscovering Potential Biomarkers. Dis Markers. 2018 Apr 10;2018:8473161. doi:10.1155/2018/8473161. PMID: 29849827; PMCID: PMC5914126.